117 related articles for article (PubMed ID: 10584064)
1. Homology modeling and substrate binding study of human CYP2C9 enzyme.
Payne VA; Chang YT; Loew GH
Proteins; 1999 Nov; 37(2):176-90. PubMed ID: 10584064
[TBL] [Abstract][Full Text] [Related]
2. The substrate binding site of human liver cytochrome P450 2C9: an approach using designed tienilic acid derivatives and molecular modeling.
Mancy A; Broto P; Dijols S; Dansette PM; Mansuy D
Biochemistry; 1995 Aug; 34(33):10365-75. PubMed ID: 7654690
[TBL] [Abstract][Full Text] [Related]
3. Homology modeling and substrate binding study of human CYP2C18 and CYP2C19 enzymes.
Payne VA; Chang YT; Loew GH
Proteins; 1999 Nov; 37(2):204-17. PubMed ID: 10584066
[TBL] [Abstract][Full Text] [Related]
4. Molecular modelling of human CYP2C subfamily enzymes CYP2C9 and CYP2C19: rationalization of substrate specificity and site-directed mutagenesis experiments in the CYP2C subfamily.
Lewis DF; Dickins M; Weaver RJ; Eddershaw PJ; Goldfarb PS; Tarbit MH
Xenobiotica; 1998 Mar; 28(3):235-68. PubMed ID: 9574814
[TBL] [Abstract][Full Text] [Related]
5. Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles.
Tracy TS; Hutzler JM; Haining RL; Rettie AE; Hummel MA; Dickmann LJ
Drug Metab Dispos; 2002 Apr; 30(4):385-90. PubMed ID: 11901091
[TBL] [Abstract][Full Text] [Related]
6. Putative active site template model for cytochrome P4502C9 (tolbutamide hydroxylase).
Jones BC; Hawksworth G; Horne VA; Newlands A; Morsman J; Tute MS; Smith DA
Drug Metab Dispos; 1996 Feb; 24(2):260-6. PubMed ID: 8742240
[TBL] [Abstract][Full Text] [Related]
7. Enzymatic determinants of the substrate specificity of CYP2C9: role of B'-C loop residues in providing the pi-stacking anchor site for warfarin binding.
Haining RL; Jones JP; Henne KR; Fisher MB; Koop DR; Trager WF; Rettie AE
Biochemistry; 1999 Mar; 38(11):3285-92. PubMed ID: 10079071
[TBL] [Abstract][Full Text] [Related]
8. Homology modelling of human cytochromes P450 involved in xenobiotic metabolism and rationalization of substrate selectivity.
Lewis DF
Exp Toxicol Pathol; 1999 Jul; 51(4-5):369-74. PubMed ID: 10445400
[TBL] [Abstract][Full Text] [Related]
9. Competitive CYP2C9 inhibitors: enzyme inhibition studies, protein homology modeling, and three-dimensional quantitative structure-activity relationship analysis.
Afzelius L; Zamora I; Ridderström M; Andersson TB; Karlén A; Masimirembwa CM
Mol Pharmacol; 2001 Apr; 59(4):909-19. PubMed ID: 11259637
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites.
Korzekwa KR; Krishnamachary N; Shou M; Ogai A; Parise RA; Rettie AE; Gonzalez FJ; Tracy TS
Biochemistry; 1998 Mar; 37(12):4137-47. PubMed ID: 9521735
[TBL] [Abstract][Full Text] [Related]
11. Arginines 97 and 108 in CYP2C9 are important determinants of the catalytic function.
Ridderström M; Masimirembwa C; Trump-Kallmeyer S; Ahlefelt M; Otter C; Andersson TB
Biochem Biophys Res Commun; 2000 Apr; 270(3):983-7. PubMed ID: 10772937
[TBL] [Abstract][Full Text] [Related]
12. Construction of a 3D model of cytochrome P450 2B4.
Chang YT; Stiffelman OB; Vakser IA; Loew GH; Bridges A; Waskell L
Protein Eng; 1997 Feb; 10(2):119-29. PubMed ID: 9089811
[TBL] [Abstract][Full Text] [Related]
13. Homology model of 1alpha,25-dihydroxyvitamin D3 24-hydroxylase cytochrome P450 24A1 (CYP24A1): active site architecture and ligand binding.
Gomaa MS; Simons C; Brancale A
J Steroid Biochem Mol Biol; 2007 Apr; 104(1-2):53-60. PubMed ID: 17240137
[TBL] [Abstract][Full Text] [Related]
14. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes.
Yamazaki H; Inoue K; Chiba K; Ozawa N; Kawai T; Suzuki Y; Goldstein JA; Guengerich FP; Shimada T
Biochem Pharmacol; 1998 Jul; 56(2):243-51. PubMed ID: 9698079
[TBL] [Abstract][Full Text] [Related]
15. Analysis of selective regions in the active sites of human cytochromes P450, 2C8, 2C9, 2C18, and 2C19 homology models using GRID/CPCA.
Ridderström M; Zamora I; Fjellström O; Andersson TB
J Med Chem; 2001 Nov; 44(24):4072-81. PubMed ID: 11708911
[TBL] [Abstract][Full Text] [Related]
16. Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9.
He M; Korzekwa KR; Jones JP; Rettie AE; Trager WF
Arch Biochem Biophys; 1999 Dec; 372(1):16-28. PubMed ID: 10562412
[TBL] [Abstract][Full Text] [Related]
17. Development of a combined protein and pharmacophore model for cytochrome P450 2C9.
de Groot MJ; Alex AA; Jones BC
J Med Chem; 2002 May; 45(10):1983-93. PubMed ID: 11985466
[TBL] [Abstract][Full Text] [Related]
18. Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors.
Ekins S; Bravi G; Binkley S; Gillespie JS; Ring BJ; Wikel JH; Wrighton SA
Drug Metab Dispos; 2000 Aug; 28(8):994-1002. PubMed ID: 10901712
[TBL] [Abstract][Full Text] [Related]
19. The substrate binding site of human liver cytochrome P450 2C9: an NMR study.
Poli-Scaife S; Attias R; Dansette PM; Mansuy D
Biochemistry; 1997 Oct; 36(42):12672-82. PubMed ID: 9335524
[TBL] [Abstract][Full Text] [Related]
20. Identification of residues 286 and 289 as critical for conferring substrate specificity of human CYP2C9 for diclofenac and ibuprofen.
Klose TS; Ibeanu GC; Ghanayem BI; Pedersen LG; Li L; Hall SD; Goldstein JA
Arch Biochem Biophys; 1998 Sep; 357(2):240-8. PubMed ID: 9735164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
